Summary

Fibromyalgia Treatment Market – Scope of Report
TMR’s report on the global fibromyalgia treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global fibromyalgia treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global fibromyalgia treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the fibromyalgia treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global fibromyalgia treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global fibromyalgia treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global fibromyalgia treatment market.

The report delves into the competitive landscape of the global fibromyalgia treatment market. Key players operating in the global fibromyalgia treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global fibromyalgia treatment market profiled in this report.

Key Questions Answered in Global fibromyalgia treatment Market Report
• What is the sales/revenue generated by fibromyalgia treatment across all regions during the forecast period?
• What are the opportunities in the global fibromyalgia treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Fibromyalgia Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global fibromyalgia treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global fibromyalgia treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global fibromyalgia treatment market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fibromyalgia Treatment Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Fibromyalgia Treatment Market Analysis and Forecast, 2017-2031
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Fibromyalgia Treatment Market Analysis and Forecast, by Treatment Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Treatment Type, 2017-2031
        6.3.1. Medications
            6.3.1.1. Pain Relievers
            6.3.1.2. Anti-Depressants
            6.3.1.3. Anti-Seizure Drugs
        6.3.2. Therapies
            6.3.2.1. Physical Therapy
            6.3.2.2. Occupational Therapy
            6.3.2.3. Counselling
    6.4. Market Attractiveness Analysis, by Treatment Type
7. Global Fibromyalgia Treatment Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2017-2031
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Fibromyalgia Treatment Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2017-2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Fibromyalgia Treatment Market Analysis and Forecast
    9.1. Introduction
    9.2. Key Findings
    9.3. Market Value Forecast, by Treatment Type, 2017-2031
        9.3.1. Medications
            9.3.1.1. Pain Relievers
            9.3.1.2. Anti-Depressants
            9.3.1.3. Anti-Seizure Drugs
        9.3.2. Therapies
            9.3.2.1. Physical Therapy
            9.3.2.2. Occupational Therapy
            9.3.2.3. Counselling
    9.4. Market Value Forecast, by Distribution Channel, 2017-2031
        9.4.1. Hospital Pharmacies
        9.4.2. Retail Pharmacies
        9.4.3. Online Pharmacies
    9.5. Market Value Forecast, by Country, 2017-2031
        9.5.1. U.S.
        9.5.2. Canada
    9.6. Market Attractiveness Analysis
        9.6.1. By Treatment Type
        9.6.2. By Distribution Channel
        9.6.3. By Country
10. Europe Fibromyalgia Treatment Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Treatment Type, 2017-2031
        10.3.1. Medications
            10.3.1.1. Pain Relievers
            10.3.1.2. Anti-Depressants
            10.3.1.3. Anti-Seizure Drugs
        10.3.2. Therapies
            10.3.2.1. Physical Therapy
            10.3.2.2. Occupational Therapy
            10.3.2.3. Counselling
    10.4. Market Value Forecast, by Distribution Channel, 2017-2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        10.5.1. Germany
        10.5.2. U.K.
        10.5.3. France
        10.5.4. Italy
        10.5.5. Spain
        10.5.6. Rest of Europe
    10.6. Market Attractiveness Analysis
        10.6.1. By Treatment Type
        10.6.2. By Distribution Channel
        10.6.3. By Country/Sub-region
11. Asia Pacific Fibromyalgia Treatment Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Treatment Type, 2017-2031
        11.3.1. Medications
            11.3.1.1. Pain Relievers
            11.3.1.2. Anti-Depressants
            11.3.1.3. Anti-Seizure Drugs
        11.3.2. Therapies
            11.3.2.1. Physical Therapy
            11.3.2.2. Occupational Therapy
            11.3.2.3. Counselling
    11.4. Market Value Forecast, by Distribution Channel, 2017-2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. China
        11.5.2. Japan
        11.5.3. India
        11.5.4. Australia & New Zealand
        11.5.5. Rest of Asia Pacific
    11.6. Market Attractiveness Analysis
        11.6.1. By Treatment Type
        11.6.2. By Distribution Channel
        11.6.3. By Country/Sub-region
12. Latin America Fibromyalgia Treatment Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Treatment Type, 2017-2031
        12.3.1. Medications
            12.3.1.1. Pain Relievers
            12.3.1.2. Anti-Depressants
            12.3.1.3. Anti-Seizure Drugs
        12.3.2. Therapies
            12.3.2.1. Physical Therapy
            12.3.2.2. Occupational Therapy
            12.3.2.3. Counselling
    12.4. Market Value Forecast, by Distribution Channel, 2017-2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. Brazil
        12.5.2. Mexico
        12.5.3. Rest of Latin America
    12.6. Market Attractiveness Analysis
        12.6.1. By Treatment Type
        12.6.2. By Distribution Channel
        12.6.3. By Country/Sub-region
13. Middle East & Africa Fibromyalgia Treatment Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Treatment Type, 2017-2031
        13.3.1. Medications
            13.3.1.1. Pain Relievers
            13.3.1.2. Anti-Depressants
            13.3.1.3. Anti-Seizure Drugs
        13.3.2. Therapies
            13.3.2.1. Physical Therapy
            13.3.2.2. Occupational Therapy
            13.3.2.3. Counselling
    13.4. Market Value Forecast, by Distribution Channel, 2017-2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.5.1. GCC Countries
        13.5.2. South Africa
        13.5.3. Rest of Middle East & Africa
    13.6. Market Attractiveness Analysis
        13.6.1. By Treatment Type
        13.6.2. By Distribution Channel
        13.6.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. Pfizer Inc.
            14.3.1.1. Company Overview
            14.3.1.2. Product Portfolio
            14.3.1.3. SWOT Analysis
            14.3.1.4. Financial Overview
            14.3.1.5. Strategic Overview
        14.3.2. Eli Lilly and Company
            14.3.2.1. Company Overview
            14.3.2.2. Product Portfolio
            14.3.2.3. SWOT Analysis
            14.3.2.4. Financial Overview
            14.3.2.5. Strategic Overview
        14.3.3. AbbVie Inc.
            14.3.3.1. Company Overview
            14.3.3.2. Product Portfolio
            14.3.3.3. SWOT Analysis
            14.3.3.4. Financial Overview
            14.3.3.5. Strategic Overview
        14.3.4. Tonix Pharmaceuticals
            14.3.4.1. Company Overview
            14.3.4.2. Product Portfolio
            14.3.4.3. SWOT Analysis
            14.3.4.4. Financial Overview
            14.3.4.5. Strategic Overview
        14.3.5. Aptinyx Inc.
            14.3.5.1. Company Overview
            14.3.5.2. Product Portfolio
            14.3.5.3. SWOT Analysis
            14.3.5.4. Financial Overview
            14.3.5.5. Strategic Overview
        14.3.6. Teva Pharmaceutical Industries Ltd.
            14.3.6.1. Company Overview
            14.3.6.2. Product Portfolio
            14.3.6.3. SWOT Analysis
            14.3.6.4. Financial Overview
            14.3.6.5. Strategic Overview
        14.3.7. Novartis AG
            14.3.7.1. Company Overview
            14.3.7.2. Product Portfolio
            14.3.7.3. SWOT Analysis
            14.3.7.4. Financial Overview
            14.3.7.5. Strategic Overview
        14.3.8. Sun Pharmaceutical Industries Limited
            14.3.8.1. Company Overview
            14.3.8.2. Product Portfolio
            14.3.8.3. SWOT Analysis
            14.3.8.4. Financial Overview
            14.3.8.5. Strategic Overview
        14.3.9. Astellas Pharma Inc.
            14.3.9.1. Company Overview
            14.3.9.2. Product Portfolio
            14.3.9.3. SWOT Analysis
            14.3.9.4. Financial Overview
            14.3.9.5. Strategic Overview
        14.3.10. Nipro Corporation
            14.3.10.1. Company Overview
            14.3.10.2. Product Portfolio
            14.3.10.3. SWOT Analysis
            14.3.10.4. Financial Overview
            14.3.10.5. Strategic Overview